logo
  

Stock Alert: Sorrento Therapeutics Down 10%

Shares of Sorrento Therapeutics, Inc. (SRNE) are currently losing nearly 10% on Monday morning following the news that Yale's saliva-based COVID-19 test received emergency use authorization from FDA, while SRNE's saliva-based test is still in development.

SRNE is currently trading at $11.20, down $1.23 or 9.93%, on the Nasdaq.

Sorrento's stock took a hit as the biotech company too has a saliva-based COVID-19 test in development. Last month, Sorrento announced it has entered into a licensing agreement with Columbia University for the rights to a rapid, one-step diagnostic test that detects SARS-CoV-2 virus in as little as 30 minutes from a sample of saliva.

Meanwhile, Yale's competing saliva-based COVID-19 test is reported to be given away for free.

The testing method is immediately available to other diagnostic laboratories that want to start using the new test, which can be scaled up quickly for use across the nation, the researchers said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tobacco giant Philip Morris International plans to stop selling cigarettes in the United Kingdom in the next decade, according to its CEO Jacek Olczak. In an interview with the Daily Mail Sunday, Olczak said the sales of the company's most popular product Marlboro cigarettes will also be stopped. The move is said to be part of the company's plan to phase out traditional tobacco products. Medallia, Inc. (MDLA), the global leader in customer and employee experience, announced Monday that it has entered into a definitive agreement to be acquired by software investment firm Thoma Bravo in an all-cash transaction that values Medallia at $6.4 billion. Under the terms of the agreement, Medallia... Shares of Philips Electronics NV were losing around 2 percent in the morning trading in Amsterdam as well as in pre-market activity on NYSE after the Dutch consumer electronics giant reported Monday weak profit due to a provision and lower orders in its second quarter, while sales were higher.
RELATED NEWS
Follow RTT